Page last updated: 2024-11-13

tat-nr2b9c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tat-NR2B9c: a synthetic peptide consisting of the C-terminal 9 amino acids of the NR2B subunit of the NMDA receptor fused to the cell membrane protein transduction domain of the HIV-1-Tat protein [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44568939
MeSH IDM0538043

Synonyms (21)

Synonym
fn023
nerinetide
na-1
fn-023
tat-nr2b9c
nerinetide [usan]
unii-d45ti2twma
l-tyrosylglycyl-l-arginyl-l-lysyl-l-lysyl-l-arginyl-l-arginyl-l- glutaminyl-l-arginyl-l-arginyl-l-arginyl-l-lysyl-l-leucyl-l-seryl-l-seryl-l-isoleucyl-l-alpha-glutamyl-l-seryl-l-alpha-aspartyl-l-valine
d45ti2twma ,
l-valine, l-tyrosylglycyl-l-arginyl-l-lysyl-l-lysyl-l-arginyl-l-arginyl-l- glutaminyl-l-arginyl-l-arginyl-l-arginyl-l-lysyl-l-leucyl-l-seryl-l-seryl-l-isoleucyl-l-alpha-glutamyl-l-seryl-l-alpha-aspartyl-
tat nr2b9c
who 10857
500992-11-0
D84054
AVA99211
AS-82902
tat-nr2b9c tfa
1834571-04-8
tat-nr2bct tfa;na-1 tfa
gtpl12332
AKOS040740169

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Our results suggest that altered activation of p38 MAPK contributes to mhtt enhancement of GluN2B/PSD-95 toxic signaling."( P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan, J; Gladding, CM; Kaufman, AM; Milnerwood, AJ; Raymond, LA; Wang, L; Zhang, LY, 2012
)
0.38
" Two minor adverse events were adjudged to be associated with NA-1; no serious adverse events were attributable to NA-1."( Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial.
Anderson, R; Bishop, J; Boulton, M; Chow, M; Clark, WM; Demchuk, AM; Dodd, R; Fleetwood, I; Garman, D; Goyal, M; Gunnarsson, T; Hill, MD; Kelly, ME; Krings, T; Lum, C; Macdonald, RL; Martin, RH; McDougall, C; Mikulis, D; Milot, G; Poublanc, J; Silver, FL; Terbrugge, KG; Tymianski, M; Wong, JH, 2012
)
0.38
" Based on the available clinical data, cationic arginine-rich peptides as a group appear to be safe when administered at therapeutic doses by a slow intravenous infusion."( Neuroprotective Cationic Arginine-Rich Peptides (CARPs): An Assessment of Their Clinical Safety.
Edwards, AB; Knuckey, NW; Mastaglia, FL; Meloni, BP, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Disks large homolog 4Homo sapiens (human)Ki8.15004.40006.20009.8000AID391156; AID391157; AID391159; AID588167
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
negative regulation of receptor internalizationDisks large homolog 4Homo sapiens (human)
signal transductionDisks large homolog 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationDisks large homolog 4Homo sapiens (human)
nervous system developmentDisks large homolog 4Homo sapiens (human)
learningDisks large homolog 4Homo sapiens (human)
synaptic vesicle maturationDisks large homolog 4Homo sapiens (human)
social behaviorDisks large homolog 4Homo sapiens (human)
protein localization to synapseDisks large homolog 4Homo sapiens (human)
locomotory exploration behaviorDisks large homolog 4Homo sapiens (human)
cellular response to potassium ionDisks large homolog 4Homo sapiens (human)
establishment of protein localizationDisks large homolog 4Homo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityDisks large homolog 4Homo sapiens (human)
regulation of long-term neuronal synaptic plasticityDisks large homolog 4Homo sapiens (human)
positive regulation of synaptic transmissionDisks large homolog 4Homo sapiens (human)
neuromuscular process controlling balanceDisks large homolog 4Homo sapiens (human)
dendritic spine morphogenesisDisks large homolog 4Homo sapiens (human)
positive regulation of protein tyrosine kinase activityDisks large homolog 4Homo sapiens (human)
protein-containing complex assemblyDisks large homolog 4Homo sapiens (human)
vocalization behaviorDisks large homolog 4Homo sapiens (human)
AMPA glutamate receptor clusteringDisks large homolog 4Homo sapiens (human)
receptor localization to synapseDisks large homolog 4Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneDisks large homolog 4Homo sapiens (human)
positive regulation of neuron projection arborizationDisks large homolog 4Homo sapiens (human)
regulation of NMDA receptor activityDisks large homolog 4Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialDisks large homolog 4Homo sapiens (human)
regulation of grooming behaviorDisks large homolog 4Homo sapiens (human)
embryo developmentDisks large homolog 4Homo sapiens (human)
postsynaptic neurotransmitter receptor diffusion trappingDisks large homolog 4Homo sapiens (human)
cell-cell adhesionDisks large homolog 4Homo sapiens (human)
chemical synaptic transmissionDisks large homolog 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
protein bindingDisks large homolog 4Homo sapiens (human)
kinase bindingDisks large homolog 4Homo sapiens (human)
protein phosphatase bindingDisks large homolog 4Homo sapiens (human)
PDZ domain bindingDisks large homolog 4Homo sapiens (human)
beta-1 adrenergic receptor bindingDisks large homolog 4Homo sapiens (human)
D1 dopamine receptor bindingDisks large homolog 4Homo sapiens (human)
P2Y1 nucleotide receptor bindingDisks large homolog 4Homo sapiens (human)
acetylcholine receptor bindingDisks large homolog 4Homo sapiens (human)
ionotropic glutamate receptor bindingDisks large homolog 4Homo sapiens (human)
protein-containing complex bindingDisks large homolog 4Homo sapiens (human)
neuroligin family protein bindingDisks large homolog 4Homo sapiens (human)
scaffold protein bindingDisks large homolog 4Homo sapiens (human)
protein kinase bindingDisks large homolog 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
plasma membraneDisks large homolog 4Homo sapiens (human)
voltage-gated potassium channel complexDisks large homolog 4Homo sapiens (human)
cytoplasmDisks large homolog 4Homo sapiens (human)
endoplasmic reticulumDisks large homolog 4Homo sapiens (human)
cytosolDisks large homolog 4Homo sapiens (human)
plasma membraneDisks large homolog 4Homo sapiens (human)
adherens junctionDisks large homolog 4Homo sapiens (human)
synaptic vesicleDisks large homolog 4Homo sapiens (human)
postsynaptic densityDisks large homolog 4Homo sapiens (human)
cell junctionDisks large homolog 4Homo sapiens (human)
endocytic vesicle membraneDisks large homolog 4Homo sapiens (human)
cortical cytoskeletonDisks large homolog 4Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneDisks large homolog 4Homo sapiens (human)
dendrite cytoplasmDisks large homolog 4Homo sapiens (human)
dendritic spineDisks large homolog 4Homo sapiens (human)
juxtaparanode region of axonDisks large homolog 4Homo sapiens (human)
cerebellar mossy fiberDisks large homolog 4Homo sapiens (human)
neuron projection terminusDisks large homolog 4Homo sapiens (human)
neuron spineDisks large homolog 4Homo sapiens (human)
synapseDisks large homolog 4Homo sapiens (human)
postsynaptic membraneDisks large homolog 4Homo sapiens (human)
excitatory synapseDisks large homolog 4Homo sapiens (human)
synaptic membraneDisks large homolog 4Homo sapiens (human)
glutamatergic synapseDisks large homolog 4Homo sapiens (human)
AMPA glutamate receptor complexDisks large homolog 4Homo sapiens (human)
basolateral plasma membraneDisks large homolog 4Homo sapiens (human)
neuron projectionDisks large homolog 4Homo sapiens (human)
postsynaptic density membraneDisks large homolog 4Homo sapiens (human)
neuromuscular junctionDisks large homolog 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID588167Inhibition of PSD-95 PDZ2 domain by competitive fluorescence polarization assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction.
AID391158Binding affinity to human PSD95 domain PDZ3 expressed in Escherichia coli BL21-DE3 by fluorescence polarization assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction.
AID391159Binding affinity to human PSD95 domain PDZ1-2 expressed in Escherichia coli BL21-DE3 by fluorescence polarization assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction.
AID391157Binding affinity to human PSD95 domain PDZ2 expressed in Escherichia coli BL21-DE3 by fluorescence polarization assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction.
AID391156Binding affinity to human PSD95 domain PDZ1 expressed in Escherichia coli BL21-DE3 by fluorescence polarization assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (7.14)29.6817
2010's23 (82.14)24.3611
2020's3 (10.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.40 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index5.54 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.45%)5.53%
Reviews4 (13.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (82.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]